Yumanity Merges With Proteostasis To Accelerate Parkinson’s Therapy
Yumanity goes public by merging with Proteostasis; it is accelerating its Parkinson’s program because of mouse model data showing disease-modifying potential. Proteostasis will out-license its CF assets.
You may also be interested in...
Finance Watch: Financial Market Turmoil Ends Amicus SPAC Deal For Gene Therapy Spinout
Public Company Edition: As their stock prices plummet, Adagio reshuffles its research plan and names a new CEO, while Yumanity restructures and seeks strategic alternatives. Also, Bristol sells $6bn worth of notes, Amgen issues $750m green bond, and Inhibrx and Amryt amend and refinance debt.
Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
Deal Watch: Merck Gets Rights To Yumanity’s Preclinical ALS, FTLD Candidates
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.